ATNM Stock Summary and Trading Ideas (Actinium Pharmaceuticals (Delaware) | AMEX:ATNM)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Actinium Pharmaceuticals (Delaware) trades on the AMEX stock market under the symbol ATNM.

As of August 28, 2026, ATNM stock price climbed to $1.01 with 110,888 million shares trading.

ATNM has a beta of 1.55, meaning it tends to be more sensitive to market movements. ATNM has a correlation of 0.09 to the broad based SPY ETF.

ATNM has a market cap of $31.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATNM traded as high as $10.24 and as low as $.74.

The top ETF exchange traded funds that ATNM belongs to (by Net Assets): VTI, VXF, IWC, BUSM.

ATNM has underperformed the market in the last year with a price return of -42.0% while the SPY ETF gained +19.7%. ATNM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.2% and -2.9%, respectively, while the SPY returned +2.2% and -0.9%, respectively.

ATNM support price is $.95 and resistance is $1.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATNM shares will trade within this expected range on the day.